As Advair Sales Fall, GSK’s Witty Reminds Investors Launches Need Time

GlaxoSmithKline’s sales of Advair nose-dived 15% in the first quarter due to pricing pressure and loss of insurance coverage. New respiratory products like Breo Ellipta have yet to make a dent toward shoring up respiratory sales.